Cancer Genetics, Icon Partner
News Jul 08, 2015
The partners will provide services from complex oncology genomic testing to core central laboratory analysis, project and data management, and sample logistics on a global basis. They will leverage Cancer Genetics' expertise in genomics and other technologies focused on cancer and Icon's know-how in strategic development and management, as well as the analysis of lab data from large-scale clinical programs.
The partnership is focused on providing a "comprehensive, integrated, and efficient solution for laboratory testing for global oncology trials from Phase I through Phase IV," they said in a statement.
Financial and other terms of the deal were not disclosed.
"This partnership will satisfy the enormous need among biotech and pharmaceutical companies for more efficient and comprehensive testing solutions by integrating [Cancer Genetics'] specialized, genomic testing [into] Icon's laboratory solutions," Cancer Genetics CEO Panna Sharma said.
Early Life Experiences Alter DNA Structure in the Adult BrainNews
Scientists report in the journal Science that the type of mothering a female mouse provides her pups actually changes their DNA.READ MORE
Worms Exhibit Fear and Respond to Anti-anxiety MedsNews
A team of investigators has uncovered new clues about the mechanisms of fear and anxiety through an unlikely creature: the tiny nematode worm.READ MORE
SMi’s 5th Annual Molecular Diagnostics Conference 2018 Agenda ReleasedNews
SMi proudly presents its 5th annual conference on Molecular Diagnostics, taking place at the Holiday Inn Kensington Forum, London, UK on 9th and 10th July 2018, with a half-day post-conference workshops on 11th July 2018.READ MORE